Intel (INTC.US) amends CHIPS Act agreement to receive $5.7 billion in cash in advance to enhance flexibility
According to Jinse Finance, Intel (INTC.US) announced on Friday Eastern Time that it has amended its CHIPS Act funding agreement with the U.S. Department of Commerce, removing previously set project milestone requirements and receiving approximately $5.7 billion in cash in advance. This move will provide Intel with greater flexibility in the use of funds.
This revised agreement is based on adjustments to the initial financing agreement from November 2024, while retaining some restrictive clauses: prohibiting Intel from using these funds for dividend distributions and stock buybacks, prohibiting certain changes in controlling ownership transactions, and prohibiting business expansion in specific countries.
As part of the agreement, Intel has issued 274.6 million shares to the U.S. government and has committed that, under certain conditions, the government can additionally subscribe for up to 240.5 million shares (i.e., the government obtains warrants).
Intel stated that it has deposited 158.7 million shares into an escrow account, which will be officially released after the government allocates more CHIPS Act funds for the "Secure Enclave program" aimed at expanding advanced chip manufacturing capacity.
The company also revealed that it has already invested at least $7.87 billion in projects that meet CHIPS Act funding requirements.
This time, the U.S. government has obtained a 9.9% equity stake in Intel. In addition, U.S. President Donald Trump stated that he plans to promote more similar deals, which has sparked doubts about the future development prospects of American enterprises.
Intel said that the U.S. government's $8.9 billion investment this time, combined with the $2.2 billion subsidy previously received by Intel, brings the total amount of government funding support it has received to $11.1 billion.
Intel CFO David Zinsner said at an investor conference on Thursday that the U.S. government's recently announced equity plan is essentially an incentive for Intel—aimed at encouraging Intel to continue to control its contract manufacturing business (i.e., foundry business).
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Chainlink's Strategic Breakout Potential: Is $31 the Gateway to a Multi-Stage Bull Run?
- Chainlink (LINK) faces critical $31 resistance in late 2025, with technical patterns suggesting potential breakout to $47–$219. - Institutional adoption surges via U.S. Commerce Department partnership, whale activity, and $2.8M token buybacks boosting liquidity. - Historical backtesting warns 30-day resistance tests often trigger 6.5% average declines, highlighting mean reversion risks. - Symmetrical triangle pattern and Elliott Wave III imply $52–$98 targets if $31 is breached, but $21–$22 retracement o

Ethereum's Institutional Momentum: Analyzing Whale Activity and Market Dynamics
- A Bitcoin whale swapped $217M BTC to ETH via Hyperliquid, signaling growing institutional preference for Ethereum over Bitcoin. - Ethereum’s price rose above $4,000 as institutions poured $4B into spot ETFs and staking yields (3.8% APY) post-2025 CLARITY Act. - Ethereum’s futures open interest hit $10B, contrasting Bitcoin’s stagnant $15.3B OI, as regulators reclassified ETH as a utility token. - Whale activity and on-chain metrics (MVRV 2.15) reinforce Ethereum’s role as the crypto economy’s backbone am

Blockchain Pioneers Redefine Drug Traceability with NFT-Driven Healthcare Pact
- NVC Health partners with QuantumCTek and North China PharmaTech to integrate blockchain in healthcare via a digital asset framework agreement. - The collaboration aims to enhance drug traceability, data security, and patient record management using NFTs and quantum computing solutions. - The initiative aligns with China's national digital transformation strategy, promoting transparency and regulatory compliance in pharmaceutical supply chains. - Industry observers highlight the partnership as a proactive

Reeves: DeFi’s Openness Will Outlast Regulatory Walls
- Fold CEO Will Reeves asserts DeFi will outlast regulatory attempts to impose biometric checks and TradFi compliance measures. - He warns such controls risk undermining DeFi's open, permissionless nature and could backfire like past internet regulation failures. - Reeves highlights growing pressure from legacy institutions to favor centralized systems over decentralized platforms through policies like ETFs. - Critics argue KYC/AML mandates would erode DeFi's privacy and censorship resistance, making it in

Trending news
MoreCrypto prices
More








